Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 12/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160923 | 0.86 | MAPKAPK5 (0.66) | MAPKAPK5FYNALK | |
| SCHEMBL10160892 | 0.85 | MAPKAPK5 (0.65) | MAPKAPK5FYN | |
| SCHEMBL10160871 | 0.85 | MAPKAPK5 (0.62) | MAPKAPK5FYNSMN1; SMN2 | |
| SCHEMBL10160945 | 0.82 | MAPKAPK5 (0.67) | MAPKAPK5FYNALK | |
| SCHEMBL10160878 | 0.81 | MAPKAPK5 (0.48) | MAPKAPK5TRPC3TRPC6HTR2C | |
| SCHEMBL10160829 | 0.79 | MAPKAPK5 (0.64) | MAPKAPK5FYN | |
| SCHEMBL10160883 | 0.79 | MAPKAPK5 (0.65) | MAPKAPK5FYNSMN1; SMN2 | |
| SCHEMBL2068760 | 0.77 | MAPKAPK5 (1.00) | MAPKAPK5FYN | |
| SCHEMBL14387664 | 0.77 | MAPKAPK5 (0.81) | MAPKAPK5FYN | |
| SCHEMBL10160918 | 0.76 | MAPKAPK5 (0.65) | MAPKAPK5FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885FYN 1037/4885GAA 3891/4885 |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885FYN 1037/4885GAA 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.